首页> 美国卫生研究院文献>International Journal of Molecular Sciences >High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors
【2h】

High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors

机译:CEBPD调节化合物的高通量筛选在THP-1衍生的报告巨噬细胞中鉴定了抗炎HDAC和BET抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study aimed to identify alternative anti-inflammatory compounds that modulate the activity of a relevant transcription factor, CCAAT/enhancer binding protein delta (C/EBPδ). C/EBPδ is a master regulator of inflammatory responses in macrophages (Mϕ) and is mainly regulated at the level of CEBPD gene transcription initiation. To screen for CEBPD-modulating compounds, we generated a THP-1-derived reporter cell line stably expressing secreted alkaline phosphatase (SEAP) under control of the defined CEBPD promoter (CEBPD::SEAP). A high-throughput screening of LOPAC®1280 and ENZO®774 libraries on LPS- and IFN-γ-activated THP-1 reporter Mϕ identified four epigenetically active hits: two bromodomain and extraterminal domain (BET) inhibitors, I-BET151 and Ro 11-1464, as well as two histone deacetylase (HDAC) inhibitors, SAHA and TSA. All four hits markedly and reproducibly upregulated SEAP secretion and CEBPD::SEAP mRNA expression, confirming screening assay reliability. Whereas BET inhibitors also upregulated the mRNA expression of the endogenous CEBPD, HDAC inhibitors completely abolished it. All hits displayed anti-inflammatory activity through the suppression of IL-6 and CCL2 gene expression. However, I-BET151 and HDAC inhibitors simultaneously upregulated the mRNA expression of pro-inflammatory IL-1ß. The modulation of CEBPD gene expression shown in this study contributes to our understanding of inflammatory responses in Mϕ and may offer an approach to therapy for inflammation-driven disorders.
机译:该研究旨在鉴定替代的抗炎化合物,其调节相关转录因子,CCAAT / Enhancer结合蛋白δ(C /EBPδ)的活性。 C /EBPδ是巨噬细胞(Mφ)中炎症反应的主调节器,主要受调节在CeBPD基因转录开始的水平。为了筛选CeBPD调节化合物,我们在定义的CeBPD启动子(CeBPD :: SeaP)的控制下稳定地表达分泌的碱性磷酸酶(SEAP)的THP-1衍生的报告细胞系。 LPAC®1280和enzo®774文库的高通量筛选LPS-and IFN-γ-活化的THP-1报道Mφ鉴定了四个表观诱导的次数:两种溴琼瘤和外虫结构域(BET)抑制剂,I-Bet151和RO 11 -1464,以及两个组蛋白脱乙酰酶(HDAC)抑制剂,SAHA和TSA。所有四次击中明显和可重复的上调的SEAP分泌和CEBPD :: SAPP mRNA表达,确认筛选测定可靠性。虽然BET抑制剂也上调了内源性CeBPD的mRNA表达,HDAC抑制剂完全废除了它。所有击中通过抑制IL-6和CCL2基因表达显示抗炎活动。然而,I-Bet151和HDAC抑制剂同时上调了促炎IL-1β的mRNA表达。本研究表明的CEBPD基因表达的调节有助于我们对Mφ中的炎症反应的理解,并可提供炎症驱动障碍治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号